Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
274.33
-3.93 (-1.41%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
What Analysts Are Saying About Amgen Stock
November 14, 2024
Via
Benzinga
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
November 13, 2024
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
November 13, 2024
Via
Benzinga
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
November 13, 2024
Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density.
Via
Investor's Business Daily
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
November 12, 2024
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could...
Via
Benzinga
3 Healthcare Stocks For Long-Term Growth And Dividends
November 07, 2024
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.
Via
Talk Markets
A Closer Look at Amgen's Options Market Dynamics
October 23, 2024
Via
Benzinga
Navigating 14 Analyst Ratings For Amgen
October 22, 2024
Via
Benzinga
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
November 12, 2024
The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
November 12, 2024
Via
Benzinga
Don’t Confuse Brains With A Bull Market, Or Price With Value
November 10, 2024
If you are interested in the stock market, maybe it is time to stop focusing on The Fed.
Via
Talk Markets
Investors Like Certainty. Trump's Win Gave Them Some.
November 08, 2024
We're also talking about Super Micro, Nvidia, and weight loss.
Via
The Motley Fool
Topics
Government
Exposures
Political
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
November 08, 2024
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
Via
Benzinga
Is Amgen Stock a Buy?
October 18, 2024
This biotech leader could be poised to rally higher.
Via
The Motley Fool
Looking Into Amgen's Recent Short Interest
October 17, 2024
Via
Benzinga
In-Depth Examination Of 11 Analyst Recommendations For Amgen
October 14, 2024
Via
Benzinga
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
November 05, 2024
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
November 05, 2024
Via
Benzinga
Amgen (AMGN) Q3 2024 Earnings Call Transcript
October 30, 2024
AMGN earnings call for the period ending September 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
October 30, 2024
The company expects to have topline results from a Phase 2 study later this year.
Via
Investor's Business Daily
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
October 30, 2024
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data.
Via
Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months.
Via
Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
October 28, 2024
One of these players has split its stock in the past. The other one hasn't.
Via
The Motley Fool
What Lies In Store For Healthcare ETFs In Q3 Earnings?
October 27, 2024
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited.
Via
Talk Markets
Topics
ETFs
2 Reliable Dividend Stocks You Can Buy and Hold Forever
October 26, 2024
There are reasons beyond the dividends to invest in these stocks.
Via
The Motley Fool
Top Stock Reports For Costco, Coca-Cola & T-Mobile US
October 25, 2024
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corp., The Coca-Cola Co., and T-Mobile US, Inc., as well as a micro-cap stock Preformed Line Products...
Via
Talk Markets
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
October 23, 2024
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.
Via
Benzinga
Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade
October 14, 2024
The analyst is closely watching MariTide, a potential monthly injection to treat obesity.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.